Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria

Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria IntroductionChronic spontaneous urticaria (CSU), which has generally replaced the former term chronic idiopathic urticaria (CIU), is defined by the presence of pruritic wheals (hives), angioedema, or both, that persist or recur for a period of at least 6 weeks and do not seem to be induced by any apparent external stimuli. The severity and duration of CSU may vary greatly among patients, while its impact on quality of life can be significant, especially in the presence of concurrent angioedema and when symptoms last for several years or fail to adequately respond to standard therapeutic interventions.According to the latest international guidelines, daily administration of nonsedating, second‐generation, H1‐antihistamines is the “gold‐standard” first‐line treatment of CSU, while dose‐escalation (up to fourfold the licensed daily dose) of H1‐antihistamines is typically followed as a second‐line approach when symptoms persist for more than 2 weeks after the initial treatment course. The use of sedating, first‐generation antihistamines for CSU treatment has been largely abandoned, particularly in Europe. Administration of these drugs (at bedtime only) is nevertheless included, as an alternative to dose advancement of H1‐antihistamines, in the US guidelines, while addition of another second‐generation antihistamine or an H2‐antagonist are among the second‐line treatment options recommended by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Dermatology Wiley

Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria

Loading next page...
 
/lp/wiley/treatment-response-to-omalizumab-in-patients-with-refractory-chronic-TH3MDG2qgq
Publisher
Wiley
Copyright
International Journal of Dermatology © 2018 International Society of Dermatology
ISSN
0011-9059
eISSN
1365-4632
D.O.I.
10.1111/ijd.13935
Publisher site
See Article on Publisher Site

Abstract

IntroductionChronic spontaneous urticaria (CSU), which has generally replaced the former term chronic idiopathic urticaria (CIU), is defined by the presence of pruritic wheals (hives), angioedema, or both, that persist or recur for a period of at least 6 weeks and do not seem to be induced by any apparent external stimuli. The severity and duration of CSU may vary greatly among patients, while its impact on quality of life can be significant, especially in the presence of concurrent angioedema and when symptoms last for several years or fail to adequately respond to standard therapeutic interventions.According to the latest international guidelines, daily administration of nonsedating, second‐generation, H1‐antihistamines is the “gold‐standard” first‐line treatment of CSU, while dose‐escalation (up to fourfold the licensed daily dose) of H1‐antihistamines is typically followed as a second‐line approach when symptoms persist for more than 2 weeks after the initial treatment course. The use of sedating, first‐generation antihistamines for CSU treatment has been largely abandoned, particularly in Europe. Administration of these drugs (at bedtime only) is nevertheless included, as an alternative to dose advancement of H1‐antihistamines, in the US guidelines, while addition of another second‐generation antihistamine or an H2‐antagonist are among the second‐line treatment options recommended by

Journal

International Journal of DermatologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off